Skip to main content

PDMR-425362-245-T

The Cancer Imaging Archive

PDMR-425362-245-T | Imaging characterization of a metastatic patient derived model of melanoma:

DOI: 10.7937/TCIA.2020.7YRS-7J97 | Data Citation Required | Image Collection

Location Species Subjects Data Types Cancer Types Size Supporting Data Status Updated
Abdomen Mouse 20 MR, SR, Other, Protocol Melanoma 2.35GB Clinical Public, Complete 2021/02/17

Summary

Pre-clinical animal models of spontaneous metastatic cancer are infrequent; the few that exist are resource intensive because determination of the presence of metastatic disease, metastatic burden, and response to therapy normally require multiple timed cohorts with animal sacrifice and extensive pathological examination. We identified and characterized a patient derived xenograft model with metastatic potential, melanoma xenograft 425362-245-T. In this study we performed a detailed imaging characterization (workflow below) of this model, which develops spontaneous lung metastases, details are provided in the attached standard operating procedures. Tumors in half of the mice were resected in the range 200-300 mm3 size; tumors in the other half were allowed to grow until it was necessary to euthanize them because of tumor size.

 

The imaging characteristics of this model (PDMR-425362-245-T) which is available from the National Cancer Institute Patient-Derived Models Repository (https://pdmr.cancer.gov/), is highly favorable for preclinical research studies of metastatic disease when used in conjunction with non-contrast T2 weighted MRI.

Results: Melanoma (PDMR-425362-245-T)

Table 1: Penetrance and location of pathological confirmed metastatic lesion(s).

# animals in group

# animals that displayed metastasis in MRI and confirmed by Pathology

Pathology confirmation of MRI (primary imaging site)

Other confirmed Location (s)

Mouse ID: MRI with pathology confirmation of metastasis

10 (non-resected)

4

(6 mice were EU due to xenograft size prior to observation of metastasis)

Lung

Kidney

1512, 1516, 1518, 1520

10 (resected)

10

Lung

Kidney, Liver, Pancreas

1506, 1508, 1509, 1510, 1511, 1515, 1517, 1519, 1521, 1523

Percent penetrance with respect to the average time-to-metastasis for non-resected (plot A: time from implant) and resected (plot B: time from tumor resection) cohorts.

Plot A

Plot B

PET/CT Characterization of the primary tumor:  Baseline PET (SOP attached) were performed when tumor reached an approximate 200 mm3.   Average SUVmax values (n=5) were calculated; [18F]FDG: 2.7 ± 0.5 and [18F]FLT: 2.0 ± 0.3.

Conclusion:

Melanoma PDMR-425362-245-T model can be challenging due to the rapid growth of the xenograft and regrowth.  Metastases was well observed on T2 MRI imaging allowing non-invasive evaluation in treatment trials.

Data Access

Version 2: Updated 2021/02/17

Added two supplementary files: 1) an example tracking spreadsheet for multi-cohort murine studies and 2) an SR Conversion Routine to convert the tracking spreadsheet parameters into a DICOM Structured Report (SR).

Title Data Type Format Access Points Subjects Studies Series Images License
Images MR, SR DICOM
Download requires NBIA Data Retriever
20 115 210 3,509 CC BY 4.0
Tracking spreadsheet for PDMR-425362-245-T Other XLSX CC BY 4.0
SR Conversion Routine (Converts a tracking spreadsheet into a DICOM Structured Report) Other ZIP CC BY 4.0
Standard Operating Procedure 50101 MRI T2 Weighted Non-Contrast Protocol Single Mouse Pulmonary Gated and Multi-Mouse Non-Gated Protocol PDF CC BY 4.0
Standard Operating Procedure 50102 Positron Emission Tomography imaging protocol (pdf, ) Protocol PDF CC BY 4.0
Related Datasets
No related Analysis Results found: Submit your proposal! No related Collections found
Legend: Analysis Results| Collections

Additional Resources for this Dataset

The National Cancer Institute (NCI) has developed a national repository of Patient-Derived Models (PDMs) comprised of patient-derived xenografts (PDXs), in vitro patient-derived tumor cell cultures (PDCs) and cancer associated fibroblasts (CAFs) as well as patient-derived organoids (PDOrg). These models serve as a resource for public-private partnerships and for academic drug discovery efforts. These PDMs are clinically-annotated with molecular information and made available in the Patient-Derived Model Repository. Data related to the specific subjects in this Collection can be found at:

The NCI Cancer Research Data Commons (CRDC) provides access to additional data and a cloud-based data science infrastructure that connects data sets with analytics tools to allow users to share, integrate, analyze, and visualize cancer research data.

 

Citations & Data Usage Policy

Data Citation Required: Users must abide by the TCIA Data Usage Policy and Restrictions. Attribution must include the following citation, including the Digital Object Identifier:

Data Citation

Tatum, J. L., Kalen, J. D., Jacobs, P. M., Ileva, L. V., Riffle, L. A., Keita, S., Patel, N., Sanders, C., James, A., Difilippantonio, S., Thang, L., Hollingshead, M. G., Phillips, J., Edmondson, E., Evrard, Y., Clunie, D. A., Liu, Y., Smith, K. E., Wagner, U., … Doroshow, J. H. (2020). Imaging characterization of a metastatic patient derived model of melanoma: (PDMR-425362-245-T) [Data set]. The Cancer Imaging Archive. https://doi.org/10.7937/TCIA.2020.7YRS-7J97

Detailed Description

In addition to images, this collection includes Raw Data Storage SOP Class instances with MR Modality, generated by a Philips MR scanner; this data is not useful to anyone without the proprietary software to interpret it.

Acknowledgements

We would like to acknowledge the individuals and institutions that have provided data for this collection:

  • Frederick National Laboratory for Cancer Research – Special Thanks to Joseph D. Kalen, PhD, Lilia V. Ileva, MS, Lisa A Riffle, Nimit Patel, Keita Saito, PhD, Yvonne Evrard, PhD, Elijah Edmondson, DVM, PhD, Jessica Phillips, Simone Difilippantonio, PhD, Chelsea Sanders, Amy James, Lia Thang, Ulrike Wagner, Yanling Liu, PhD, John B. Freymann, and Justin Kirby.
  • Division of Cancer Therapeutics and Diagnosis/National Cancer Institute - James L. Tatum, MD, Paula M Jacobs, PhD, Melinda G. Hollingshead, DVM, and James H. Doroshow, MD
  • PixelMed Publishing – Special Thanks to David A. Clunie, MD
  • University of Arkansas for Medical Sciences – Special Thanks to Kirk E. Smith
  • This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, under Contract Number HHSN261201500003I. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government.

Related Publications

Publications by the Dataset Authors

The authors recommended this paper as the best source of additional information about this dataset:

No publications by dataset authors were found.

Research Community Publications

TCIA maintains a list of publications which leverage TCIA data. If you have a manuscript you’d like to add please contact the TCIA Helpdesk.

Other Publications Using this Data

TCIA maintains a list of publications which leverage TCIA data. If you have a manuscript you’d like to add please contact the TCIA Helpdesk.

Previous Versions

Version 1: Updated 2020/05/22

Title Data Type Format Access Points Subjects Studies Series Images License
Images DICOM
Download requires NBIA Data Retriever
Standard Operating Procedure 50101 MRI T2 Weighted Non-Contrast Protocol Single Mouse Pulmonary Gated and Multi-Mouse Non-Gated
Standard Operating Procedure 50102 Positron Emission Tomography imaging protocol PDF